Применение атипичных нейролептиков в лечении больных параноидной шизофренией, страдающих сахарным диабетом типа 2
Диссертация
У больных, принимающих атипичные антипсихотические препараты (АА) -оланзапин, клозапин, кветиапин, развитие сахарного диабета (СД) происходит в более ранние сроки и в более молодом возрасте, чем у пациентов, получающих классические нейролептики (галоперидол). Сроки формирования СД у больных принимающих галоперидол, соответствуют тенденциям в общей популяции. В случаях, описанных в п.п. 2.1 и 2.2… Читать ещё >
Список литературы
- Авруцкий Г. Я., Гурович И. Я., Громова В. В. Фармакотерапия психических заболеваний М.: Медицина, 1974. — 471 с.
- Аведисова A.C. Неблагоприятные события при терапии нейролептиками: побочные эффекты и осложнения // Психиатрия и психофармакотерапия. -2007.-Т. 9-№ 5.-С. 14−18.
- Акмаев И.Г. Нейроиммунноэндокринология: факты и гипотезы // Проблемы эндокринологии. — 1997. Т.43. — № 1. — С. 3−9.
- Балаболкин М.И. Диабетология. М.: Медицина. — 2006. — 672 с.
- Бойцов С.А., Голощапов A.B. Связь основных параметров метаболического сердечно-сосудистого синдрома со степенью нарушения углеводного обмена и выраженностью абдоминального ожирения у мужчин // Артериальная гипертензия. 2003. — Т. 9. — № 2. — С. 47 — 51.
- Буланов B.C. Нейроэндокринные побочные эффекты длительной терапии рисперидоном больных с шизоаффективным расстройством и параноидной шизофренией (прогноз, коррекция). Автореф. дис. канд. мед. наук. М.: 2005. -21 с.
- Гинзбург М.М. Ожирение и метаболический синдром. Влияние на состояние здоровья, профилактика и лечение. Самара: Парус, 2000. — 160с. I
- Гинзбург М.М., Козупица Г. С. Значение распределения жира при ожирении// Проблемы эндокринологии. 1996. — Т. 42. — № 6.- С. 30−34.
- Горобец JI.H. Нейроэндокринные дисфункции у больных шизофренией и шизоаффективным расстройством в условиях современной антипсихотической терапии (клинико-биохимическое исследование): Автореф. дис. докт. мед. наук. М.: 2007. 50 с.
- Горобец JI.H. Нейроэндокринные дисфункции у больных шизофренией // Социальная и клиническая психиатрия. 2005.- т. 15. — вып. 1 — С.89−99.
- Горобец JI.H. Нейроэндокринные дисфункции и нейролептическая терапия. М.: ИД «МЕДПРАКТИКА — М», 2007 г. — 312с.
- Дедов И.И., Мельниченко Г. А., Фадеев В. В. Эндокринология. Учебник для вузов. Гэотар Медицина, 2007. — 432 с.
- Дедов И.И., Шестакова М. В. Сахарный диабет. Руководство для врачей. -М.: Универсум Паблишинг, 2003. 455с.
- Дробижев М.Ю. К проблеме сахарного диабета у больных шизофренией (по материалам некоторых- публикаций в журналах США)// Психические расстройства в общей медицине. 2007. — № 2 — с. 35−37.
- Коркина М.В., Лакосина Н. Д., Личко А. Е., Сергеев И. И. Психиатрия: Учебник 2-е изд., доп., перераб. — М.: МЕДпресс — информ, 2002. — 576 с.
- Крылов В.И. Метаболические эффекты атипичных нейролептиков // Российский психиатрический журнал. 2004. — № 3. — С.47−51.
- Применение методов статистического анализа для изучения общественного здоровья и здравоохранения: Учебное пособие для практических занятий / Под ред. чл.-корр. РАМН В. З. Кучеренко. М.: «ГЭОТАР — Медиа», 2006. — 192 с.
- Малин Д.И. Современные подходы к проблеме интолерантности к психофармакотерапии у больных эндогенными психозами // Психиатрия и психофармакотерапия. 2003.- Т. 5 — № 1.- с. 38−40.
- Макарова Н.В., Трофимец В. Я. Статистика в Excel: Учебное пособие. М.: «Финансы и статистика». 2003. — 386 с.
- Мартынихин И.А. Метаболический синдром и факторы риска его развития среди госпитализированных больных параноидной формой шизофрении// Социальная и клиническая психиатрия. 2009. — Т. 19. — № 1. — С. 24−28.
- Метаболический синдром / Под ред. чл.-корр. РАМН Г. Е. Ройтберга. -М.: МЕД пресс-информ, 2007. — 224 с.
- Мкртумян A.M., Бирюкова Е. В. Сахарный диабет типа 2 с метаболическим синдромом: способы коррекции основных метаболических и гемодинамических нарушений / Справочник поликлинического врача. 2007. -№ 6. С. 36−41.
- Мкртумян A.M., Бирюкова Е. В., Покхарел Б. Клинические аспекты метаболического синдрома // Современная стратегия в лечении сахарного диабета: тез. докл. науч. практ. конф. 19 ноября М.: ФГУ УНМЦ УДП РФ, 2008-С. 39−41.
- Морозова М.А. Резистентность к антипсихотикам и возможности оланзапина в рефрактерных к терапии случаях шизофрении // Психиатрия и психофармакотерапия. 2002.- Т. 84-№ 3 — С. 113−118
- Морозова М.А., Жаркова Н. Б., Бениашвили А. Г. Опыт применения атипичного нейролептика оланзапина в остром периоде шизофрении // Журн. неврол. и психиатр. — 2000. — № 4.- С. 37−43.
- Мосолов С.Н. Биологические основы современной антипсихотической терапии // Российский психиатрический журнал. 1998. -№ 6. — С. 7−12
- Мосолов С.Н. Резистентность к психофармакотерапии и методы ее преодоления // Психиатрия и психофармакотерапия. 2002.- Т. 4 — № 4.- С. 132−136
- Мосолов С.Н., Кабанов С. О., Метаболические нарушения при антипсихотической терапии // Социальная и клиническая психиатрия. 2003. -т. 13.-вып. 2.-С. 162−171.
- Мосолов С.Н., Рыбкин П. В., Сердитов О. В., Ладыженский М. Я., Потапов А. В. Метаболические побочные эффекты современной антипсихотической терапии // Социальная и клиническая психиатрия. 2008. — т. — вып. 3. — С. 75−90.
- Носков С.Н. Сахарный диабет. Ростов-на-Дону: Феникс, 2007. — 574с.
- Нуллер Ю.Л. Практические аспекты психофармакотерапии: трудности и ошибки // Психиатрия и психофармакотерапия. 2002.- Т. 4 — № 1.- с. 16−18.
- Пальцев М.А., Кветной И. М. Руководство по нейроиммуноэндокринологии. М.: ОАО «Издательство „Медицина“, 2006. -384с.
- Петрюк П. Т. Основные современные принципы применения психофармакотерапии в психиатрии // Таврический журнал психиатрии. — 2004. — Т. 8, № 3. — С. 27−33.
- Попов М.Ю. Фармакотерапия шизофрении: анализ объективных трудностей // Российский психиатрический журнал. 2003. -№ 4. — с. 41−45.
- Цыганков Б.Д., Агасарян Э. Г. Современные и классические антипсихотические препараты: сравнительный анализ эффективности и безопасности // Психиатрия и психофармакотерапия. 2006.- Т. 8 — № 6.- С. 31−37.
- Шестакова М.В., Дедов И. И. Пути профилактики сахарного диабета типа 2. // Сахарный диабет. 2002. — 4 (17). С. 34−38.
- Ai D., Roper Т.А., Riley J.A. Diabetic ketoacidosis and clozapine. // Postgrad Med J. 1998- 74: P. 493−494.
- Allison D.B., Casey D.E. Antipsychotic-induced weight gain: a review of the literature // J. Clin. Psychiatry 2001- 62: (suppl 7): P. 22−31.
- Allison D.B., Fontaine K.R. Heo M. et. al. The distribution of body mass index among individuals with and without schizophrenia // J. Clin. Psychiatry. -1999- 60: P. 215−220.
- Allison D.B., Mentore J.L., Heo M. Antipsychotic-induced weight gain: a comprehensive research systhesis // Am. J. Psychiatry. 1999- 156: P.1686−1696.
- Bai Y. M., Lin C.C., Chen J.Y., et al. Weight gain among patients on clozapine // Psychiatr Serv. 1999. — Vol. 50. — P. 704−705.
- Banerji M.A. Impaired beta cell and alpha-cell function in African-American children with type 2 diabetes mellitus: „Flatbush diabetes“ // J. Pediatric Endocrinol Metab. 2002. — 15 (suppl 1): P. 177−181.
- Baptista T. Body weight• induced by antipsychotic drugs: mechanisms and management // Acta Psychiatr. Scand. 1999. — Vol. 100. — 3−16.
- Barnes T.R.E. A rating scale for drug-induced akathisia // British J. Psychiatry. -1989.-Vol. 154: P.672−676.
- Basson BR, Kinon BJ, Taylor CC, et. al. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone // J Clin Psychiatry. 2001- 62: P. 231−238.
- Basu A., Meltzer H.Y. Differential trends in prevalence of diabetes and unrelated general medical illness for schizophreniapatients before and after the atypical antipsychotic era // Schizoph. Research. 2006- 86: P. 99 — 109.
- Beasley CM, Dellva MA, Tamura RN ct al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol // Br J Psychiatry. -1999.-174:P.23—3 0.
- Best L., Yates A.P., Reynolds G.P. Actions of antipsychotic drugs on pancreatic13. cell function: contrasting effects of clozapine and haloperidol // J, Psychopharmacology/ 2005. — Vol. 19. — №. 6. — P. 597−601.
- Blin O., Micallef J. Antipsychotic-associated weight gain and clinical outcome parameters //J. Clin Psychiatry. 2001- 62 (suppl 7): P. 11−21.
- Boden G., Shulman G.L. Free acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and (3-cell dysfunction // Eur. J. Clin. Invest. 2002. — 32 (Suppl. 3): P. 14−23.
- Brandt G.T., Norwood A.E., Ursano R.J. Diabetic ketoacidosis associated with clozapine treatment// Am. J. Psychiatry. 1995- 151: P. 1520−1521.
- Brecher M., Rak I.W., Westhead E.K. et.al. The long-term effect of quetiapine ('Seroquel') monotherapy on weight in patients with schizophrenia// Int. J Psychiatry Clin. Pract. 2000:4: P.287−292.
- Brown S., Inskip H., Barraclough B. Causes of the excess mortality of schizophrenia // Brit J Psychiatry. 2000- 177: P. 212−217.
- Burton, T: New antipsychotic-drug class is tied to increase in diabetes // Wall Street Journal. 2003. — August 22: B4.
- Bustillo J.R. Buchanan R.W. Irish D. et.al. Differential effect of clozapine onweight: a controlled study// Am. J. Psychiatry. 1996: 153: P. 817−819.
- Buse J.B., Cavazzoni P., Hornbuckle K. et. al. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States // J. Clin. Epidemiology. 2003.56: P. 164−170.
- Bushe C., Holt R. Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia // The British Journal of Psychiatry. -2004. 184: P. 67−71.
- Caro J.J., Ward A., Levinton C. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis // J. Clin. Psychiatry.-2002.-63:P.l 135−1139.
- Casey D.E., Haupt D.W., Newcomer J.W., et. al. Antipsychotic induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia // J. Clin. Psychiatry. — 2004- 65 (suppl 7): P. 4 — 18.
- Cavazzoni P., Mukhopadhyay N., Carlson C., Breier A. Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications // British J. Psychiatry. 2004. — 184: P. 94 101.
- Chakos M., Lieberman J., Hoffman E. et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials //Am J Psychiatry. 2001- 158: P. 518−526.
- Citrome L., Jaffe A., Levine J., et. al. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients // Psychiatric Services. 2004. — 55: P. 1006−1013.
- Citrome L.L., Jaffe A.B. Relationship of atypical antipsychotics with development of diabetes mellitus // Annals of Pharmacotherapy. — 2003. -Vol. 37. -№ 12.-P. 1849−1857.
- Cohn T.A., Remington G. Risk factors for coronary heart disease in longer-term patients on antipsychotic medication: high prevalence of syndrome X // Schizophr Res. 2003- 60: P. 353−354.
- Conley RR, Mahmoud R: A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder // Am J Psychiatry. 2001- 158: P.765−774
- Czobor P., Volavka J., Sheitman B. et al. Antipsychotic-induced weight gain and therapeutic’response: a differential association // J Clin Psychopharmacol. -2002. Vol. 22. — P. 244−251.
- Dagli A. J. Severe hyperglycemia following ingestion of chlorpromazine// J. Assoc. Physicians India. 1984. — 32. -P. 762−763.
- Davis J.M., Chen N., Glick I.D. A Meta-analysis of the Efficacy of Second-Generation Antipsychotics. //Arch Gen Psychiatry. 2003. — Jun- 60: P. 553 — 564.
- Dixon L., Postrado L., Delahanty J. The association of medical comorbidity in schizophrenia with poor physical and mental health // J Nevr Ment Dis. 1999- 187: P. 496−502.
- Domon S.E., Cargile C.S. Quetiapine associated hyperglycemia and hypertriglyceridemia // J. American Academy of Child and Adolescent Psychiatry 2002.-41: P. 495−496.
- Druss B.G., Bradford W.D., Rosenheck R.A. Quality of medical care and excess mortality in older patients with mental disorders // Arch Gen Psychiatry. -2001- 58: P.565−572.
- Dwyer D.S., Pinkofsky H.B., Lie Y, Bradley R.J. Antypsychotic drugs affect glucose uptake and the expression of glucose trasporters in PC 12 cells // Prog. Neuropsychopharmacol Biol Psychiatry. 1999- 23: P. 69−80.
- Eckel R.H., Krauss R.M. American Heart Association call to action: obesity as a major risk factor for coronary heart disease // Circulation. 1998. — 97: P. 2099 -2100.
- Federspil G., Casar D., Stautffacher W. Chlorpromazine in the treatment of endogenous organic hyperinsulinism // Diabetologia. 1974. — Vol. 10. — P. 189 191.
- Feldman P.D., Hay L.K., Deberdt W., et al. Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States // J Am Med Dir Assoc. 2004- 5: P.38−46.
- Fenton W.S., Chavez M.R. Medication-induced weight gain and dyslipidemia in patients with schizophrenia // Am J Psychiatry. 2006 October. — 163: P. 1697−1704.
- Fontaine K.R., Heo M., Harrigan E.P. Estimating the consequences of antipsychotic induced weight gain on health and mortality rate // Psychiatry Res. -2001- 101: P.277−288.
- Fuller M.A., Shermock» K.M., Secic M., et al. Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine // Pharmacotherapy 2003- 23: P. 1037−1043.
- Gianfrancesco F.D., Grogg A.L., Mahmoud R.A. et. al. Differential effects of risperidone, olanzapine, clozapine and conventional antipsychotics on type 2diabetes: findings from a large health plan database // J. Clin. Psychiatry. 2002. 63: P. 920−930.
- Gianfrancesco F.D., White R, Wang R, Nasrallah H: Antipsychotic-induced type 2 diabetes: evidence from a large health plan database // Journal of Clinical Psychopharmacology. 2003- 23 (August): P. 328−335.
- Glick I.D., Fryburg D., O’Sullivan R.L., et. al. Ziprasidone’s benefits versus olanzapine on weight gain and insulin resistance // Presented at the 154th annualmeeting of the American Psychiatric Association- May 5- 10, 2001- New Orleans.
- Goldman H.H., Skodol A.E., Lave T. R. Revising Axis V for DSM IV: A Revising of Measures of Social Functioning // Am J Psychiatry. — 1992. — 149. — P. 1148−1156.
- Goldstein L., Sporn J., Brown S., et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment // Psychosomatics. -1999- 40: P.438−443.
- Graham K.A., Perkins D.O., Edwards L.J., et. al. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis // Am J Psychiatry. 2005. Jan. -162: P. 118−123.
- Green A.I., Patel J.K., Goisman R.M. et.al. Weight gain from novel antipsychotic drugs: need for action// Gen. Hosp. Psychiatry. 2000. 22: P. 224 235.
- Guy W. Clinical Global Impressions. In: ECDEU Manual, NIMH Rockville, Makyland: US Dept. of Health and Human Services. 1976. — P. 217−222.
- Haddad P.M. Antipsychotics and diabetes: review of non-prospective data // British J Psychiatry. 2004. — 184 (suppl. 47): P. 80−86.
- Hagg S. Soderberg S., Ahren B. et. al. Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics // J Clin. Psychiatry. -2001.- Nov. 62(11): P. 843−848.
- Hanley A. J., Williams K., Stern M.P. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study// Diabetes Care. 2002- 25: P. 1177−1184.
- Hanssens L., van Winkel R., Wampers M. et al. A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schzoaffective disorder// Schizophr Res. 2008 Dec- 106 (2−3): P. 308−14.
- Harris M.I., Flegal K.M., Cowie C.C. Prevalence of diabetes, impaired fasting glucose tolerance in US adults: the Third National Health and Nutrition Examination Survey, 1988−1994 // Diabetes Care. 1998- 21: P. 518−524.
- Haupt D.W., Newcomer J.W., Hyperglycemia and antipsychotic medications // J Clin Psychiatry. 2001- 62(suppl 27): P. 15−26.
- Heiskanen T., Niskanen L., Lyytikainen R. et al. Metabolic syndrome in patients with schizophrenia // J. Clin Psychiatry. 2003- 64: P.575−579.
- Henderson D. C. Clozapine: diabetes mellitus, weight gain, and lipid abnormalities// J. Clin Psychiatry. 2001- 62: Suppl. 23: P. 39 44.
- Henderson D. C., Cagliero E., Gray C., et. al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study // Am J Psychiatry. 2000. — 157: P. 975−981.
- Hennekens C.H., Hennekens A.R., Hollar D. et.al. Schizophrenia and increased risks of cardiovascular disease// Am. Heart J. 2005- 150: P. 11 151 121.
- Hiles B.W. Hyperglycemia and glucosuria following chlorpromazine therapy (letter). JAMA, 1956, 162: P. 1651.
- Holt R.I.G., Bushe C., Citrome L. Diabetes and schizophrenia 2005: are we any closer to understanding the link? // J. Psychopharmacology. 2005. — Vol. 19.-№.6.suppl.-P.56−65.
- Hong C.J., Lin C.H., Yu Y.W., et al. Genetic variants of the serotonin systemand weight gain during clozapine treatment //Pharmacogenetics. 2001. — Vol. 11. -P. 265−268.
- Hosojima H., Togo T., Odawara T. Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia // J. Psychopharmacology. 2006. — Vol. 20. — №. 1. — P. 75−79.
- Howes O.D., Bhatnagar A., Gaughran F.P., et.al. A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance // Am J Psychiatry. 2004. Feb. — 161: P. 361−363.
- Howes O.D., Rifkin L. Diabetic keto-acidotic (DKA) coma following olanzapine initiation in a previously euglycaemic woman and successful continued therapy with olanzapine // J. Psychopharmacology. 2004. -Vol. 18. -№. 3. — P. 435−437.
- Isomaa B., Almgren P., Tuomi T. Cardiovascular morbidity and mortality associated with the metabolic syndrome // Diabetes Care 2001- 24: P.683−689.
- Jaton L., Kinon B.J., Rotelli M. Differential rate of weight gain present among patients treated with olanzapine abstract. // Schizophr Res. 2003- 60: P. 357.
- Jaffe A.B., Levine J. Antipsychotic medication coprescribing in a large state hospital system // Psychopharmacology and Drug Safety. — 2003. 12: P. 41 — 48.
- Jin H., Meyer J.M., Jeste D.V. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases// Ann. Clin. Psychiatry.- 2002.14: P. 59−64.
- Jones A.M., Rak I.W., Raniwalla J. Weight changes in patients treated with quetiapine poster. Presented at the 153rd annualmeeting of the American Psychiatric Association- May 13−18, 2000- Chicago, III.
- Kahn B.B. Filer J.S. Obesity and insulin resisteance// J. Clin. Invest. 2000. -106: P. 473−481.
- Kane J., Honigfeld G., Singer J., Meitzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine // Arch Gen Psychiatry. 1988. — Sep. — 45: P. 789 — 796.
- Kasanin J. The blood sugar curve in mental disease // Arch Neurol Psychiatry 1926- 16: P. 414−419.
- Kasin E., Parker S. Schizophrenia and diabetes // Am J Psychiatry. — 1943. — May. 99: P.793−797.
- Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia// Schizophr. Bull. 1987- 76: P. 1−100.
- Koller E.A., Cross J.T., Doraiswamy P.M., et. al. Risperidone associated diabetes mellitus: a pharmacovigilance study // Pharmacotherapy. — 2003. — 23: P. 735−744.
- Koller E.A., Doraiswamy P.M. Olanzapine associated diabetes mellitus // Pharmacotherapy. — 2002. — 22: P. 841 — 852.
- Koller E.A., Schneider B., Bennett K., et. al. Clozapine associated diabetes // Am. J, Medicine. — 2001. — 111: P. 716 — 723.
- Koller E.A., Weber J., Doraiswamy P.M., et. al. A survey of reports of quetiapine associated hyperglycemia and diabetes mellitus // J. Clin. Psychiatry. 2004.-65: P. 857−863.
- Koro C. E., Fedder D.O., L’Italien G.J., et. al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients // Arch Gen Psychiatry. 2002−59: P. 1021−1026.
- Kostakoglu A., Yazici K., Erbas T., Guvener N. Ketoacidosis as a side-effect of clozapine: a case report // Acta Psychiatr Scand. 1996- 93: P. 217−218.
- Lafayette J.M., Pirl W.F., Henderson D.C. Low-dose clozapine and diabetic ketoacidosis // Psychosomatics. May-June 2003. — 44: 3.
- Lambert B.L., Cunningham F.E., Miller D.R., et al. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in Veterans Health Administration Patients with schizophrenia // American J Epidemiology. 2006. -164(7): P. 672−681.
- Lambert T. Hares and tortoises: long-term antipsychotic weight gain // 7th Biennal Australian Schizophrenia Conference. 24−26 Oct 2002- Sydney, NSW.
- Lambert T. Chapmen L.H. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement// MJA, 2004- 181 (10): P. 544−548.
- Lamberti J.S., Olson D., Crilly J.F., et al. Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry. 2006. — 163: P. 1273−1276.
- Lean M.E.J., Pajonk F-G. Patients on atypical antipsychotic drugs another high-risk group for type 2 diabetes // Diabetes Care. 2003. — 26: P. 1597−1605.
- Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia // N Engl J Med 2005- 353: P. 12 091 223.
- Lindenmayer J.P., Czobor P., Volavka J., et. al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics // Am J Psychiatry. 2003. — 160: P. 290−296.
- Lindenmayer J.P., Patel R. Olanzapine-induced ketoacidosis with diabetes mellitus // Am J Psychiatry. 1999. — Sep. -156: P.1471.
- Lipscombe L.L., Levesque L., Gruneir A., Fischer H.D. et al. Antipsychotic drugs and hyperglycemia in older patients with diabetes // Arch Intern Med. -2009- 169(14): P. 1282−1289. ,
- L’ltalien G. Pharmacoeconomic impact of antipsychotic-induced metabolic events // Preventative Medicine in Managed Care. 2003- 3: P. 38−42.
- Llorente M., Malphurs J., Feil D. Psychiatric Disorders and Diabetes Mellitus. Oxford, Taylor and Francis, 2007, P. 260.
- Lund B.C., Perry P.J., Brooks J.M., Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension // Arch Gen Psychiatry. -2001- 58: P. 1172−1176.
- Mackin P., Bishop D., Watkinson H., et. al. Metabolic disease and cardiovascular risk in people treated with antipsychotics in the commity // British J Psychiatry. 2007. -191: P. 23 -29.
- Mclnture R.S., Mancini D.A., Basile V.S. Mechanisms of antipsychotic-induced weight gain // J. Clin. Psychiatry. 2001. 62: Suppl. 23: P. 23−29.
- Meduna L.J., Gerty F.J., Urse V.G. Biochemical disturbances in mental disorders // Arch. Neurol. Psychiatry. 1942- 47: P. 38 — 52.
- Meguid M.M., Fetissov S.O., Varma M., et al. Hypothalamic dopamine and serotonin in the regulation of food intake // Nutrition. 2000. — Vol. 16. — P. 843 857.
- Melkersson K., Hulting A.L. Recovery from new-onset diabetes in a schizophrenic man after withdrawal of olanzapine // Psichosomatics. 2002. -Feb.- 43:1.-P. 67−70.
- Melkersson K., Hulting A. L, Brismar K. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses // J. Clin. Psychiatry. 2000 Oct- 61 (10): P. 742 — 749.
- Meyer J.M. Novel antipsychotics and severe hyperlipidemia // J Clin Psychopharmacol. 2001- 21: P. 369−374.
- Moncrieff J. Clozapine v. conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination // Br. J. Psychiatry. 2003 Aug — 183: P. 161 — 166.
- Morgan D. Audit of metabolic syndrome in adults prescribed clozapine in community and long-stay in-patient populations // Psychiatric Bulletin. 2008. -32: P. 174−177.
- Mortensen P.B., Juel K. Mortality and causes of death in first admitted schizophrenic patients// Brit J Psychiatry. 1993- 163: P. 183−189.
- Mortimer A. Treatment of the patient with long-term schizophrenia // Advances in Psychiatric Treatment. 1997- 3: P. 339−46.
- Mukherjee S., Decina P., Bocola V., et al. Diabetes mellitus in schizophrenic patients // Compreh. Psychiatry. 1996. — Vol. 37. — P. 68−73.
- Mukherjee S., Roth S.D., Sandyk R., et al. Persistent tardive and neuroleptic effects on glucose tolerance // Psychiatry Res. 1989- 29: P. 17−27.
- Nasrallah H.A. Atypical antipsychotic-induced metabolic side effects insights from receptor-binding profiles // Mol Psychiatry. -2008 Jan- 13 (1): P. 27−35.
- Nemeroff C.B. Dosing the antipsychotic medication olanzapine // J Clin Psychiatry. -1997- 58 (suppl 10): P. 45−49.
- Newcomer J.W., Haupt D.W., Melson A.K. Fasting plasma lipids, glucose and insulin, and C-reactive protein are related to adiposity in schizophrenia patients and controls abstract. // Abstr Soc Neurosci. 2002: 895.16.
- Newcomer J.W., Haupt D.W., Fucetola R., et. al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia // Arch Gen Psychiatry. -2002- 59: P. 337−345.
- Newman S.C., Bland R.C. Mortality in a cohort of patients with schizophrenia: a record linkage study // Can. J. Psychiatry. 1991- 36: P. 239 245.
- Ohlson L.O., Larsson B., Svardsudd K. The influence of body fat distribution on the incidence of diabetes mellitus: 13.5 years of follow-up of the participants in the study of men born in 1913 // Diabetes. 1985- 34: P. 1055−1058.
- Procyshyn R.M., Pande S., Tse G. New onset diabetes mellitus associated with quietapine // Canadian J. Psychiatry. — 2000. — 45: P. 668 — 669.
- Redelmeier D.A., Tan S.H., Booth G.L. The treatment of unrelated disorders in patients with chronic medical diseases // N Engl J Med. 1998- 338: P.1516−1520.
- Ryan M., Collins P., Thakore J. H., Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia // Am J Psychiatry. -2003. -Feb. 160: P. 284−289.
- Schultz S. K., Arndt S., Ho B. C., et al. Impaired glucose tolerance and abnormal movements in patients with schizophrenia // Am J Psychiatry. — 1999. — April. 156: P.640−642.
- Schwenkreis P., Assion H-J. Atypical antipsychotics and diabetes mellitus // World J Biological Psychiatry. 2004. -V.5, N 2, P.73−83.
- Sernyak M. J., Leslie D. L., R .D. Alarcon, et. al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia // Am J Psychiatry. 2002- 159: P. 561−566.
- Simpson G.M., Angus J.W.S. A rating scale for extrapyramidal side effects. // Acta Psychiatrica Scandinavica .- 1970- suppl 212: P. 11−19.
- Sobel M., Jaggers E.D., Franz M.A. New onset diabetes mellitus associated with the initiation of quietiapine treatment// J. Clin. Psychiatry. — 1999.-60: P. 556−557.
- Starrenburg F.C.J., Bogers J.P.A.M. How can antipsychotics cause diabetes mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins // European Psychiatry. 2009- 24- P. 164 — 170.
- Stassen H.H., Bridler R., Flagele S. Schizophrenia and smoking: evidence for a common neurobiological basis // Am J Med Genet. 2000- 96: P. 173−177.
- Sussman N. Review of atypical antipsychotics and weight gain // J Clin Psychiatry.-2001.-Vol. 26.-P. 137−141.
- Takahashi S., Moriwaki Y., Tsutsumi Z. Increased visceral fat accumulation further aggravates the risk of insulin resistance in gout// Metabolism. 2001. — 50 (4): P. 393−398.
- Taylor D.M., Mcaskill R. Atypical antipsychotics and weight gain a systematic review // Acta Psychiatrica Scandinavica. — 2000. 101: P. 416 — 432.
- Taylor D., Young C., Mohamed R., et al. Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs // J. Psychopharmacology. 2005. — Vol. 19. -№. 2. — P. 182−186.
- Thakore J.H. Metabolic syndrome and schizophrenia // British J Psychiatry. -2005.-186: P. 455−456.
- Thonnard-Neumann E. Phenothiazines and diabetes in hospitalized women// Am J Psychiatry 1956. — Vol. 29. — P. 827−828.
- Thonnard-Neumann E. Phenothiazines and diabetes in hospitalized women // Am J Psychiatry. 1968. — Jan. — 124: P. 978−982.
- Tighe S., Dinan T. An overview of the central control of weight regulation and the effect of antipsychotic medication // J Psychopharmacology. -2005. Vol. 19. — №. 6. — suppl. P. 36−46.
- Toalson P., Saeeduddin A., Hardi T., Kabinoff G. The metabolic syndrome in patients with severe mental illnesses. // J Clin Psychiatry. 2004- 6: P. 152−158.
- Toni R. The neuroendocrine system: organization and homeostatic role // J. Endocrinol. Invest. 2004. -Vol. 27 (Suppl. 6). — P. 35−47.
- Varma M.K., Connolly K., Fulton B. Life-threatening hyperglycemia and acidosis related to olanzapine: a case report and review of the literature // J Intensive Care Medicine. -2007. Vol. 22. — №. 1. — P. 52−55.
- Vik-Mo A.O., Birkenaes A.B., Ferno J., et al. Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated // International J Neuropsychopharmacology. 2008. -11. -P. 679−684.
- Wang P. S., Glynn R.J., Ganz D.A. el.al. Clozapine use and risk of diabetes mellitus // J. Clin. Psychopharmacology. 2002. 22: P. 236 — 243.
- Wehring H.J., Kelly D.L., Love R. C., Conley R. R. Deaths from diabetic ketoacidosis after long-term clozapine treatment // Am J Psychiatry. -2003. -Dec. -160: P. 2241−2242.
- Weyer C., Funahashi T., Tanaka S. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia// J. Clin. Endocriol. Metab.-2001.-86: P. 1930−1935.
- Willett W.C., Dietz W.H., Colditz G.A. Guidelines for healthy weght // N Engl J Med. 1999- 341: P. 427−434.
- Wirshing D.A., Spellberg G.J., Erhart S.M., et al. Novelantipsychotics and new-onset diabetes // Biol Psychiatry. 1998- 44: P. 778−783.
- Wozniak K.M., Linnoila M. Hyperglycemic properties of serotonin receptor antagonists// Life Sci. 1991. — Vol. 49. — P. 101−109.
- Yang S.H., McNeely M.J. Rhabdomyolysis, pancreatitis, and hyperglycemia with ziprasidone letter. // Am J Psychiatry. 2002- 159: P. 1435.
- Zemel M.B. Insulin resistance, obesity and hypertension: an overview // J Nutr. 1995. — P. 1715−1717.
- Zhang Z-J., Yao Z-J., Fang Q., et al. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels // The British J. Psychiatry. -2004.- 184: P. 58−62.